Company intelligence / Profile preview

Calyx

Winston-Salem, North Carolina, United States

Ownership: Private
Development stage: Other

Overview

Calyx has enabled the development of over 650 approved medical treatments, including 70+ recognized with Breakthrough Therapy designation, by providing advanced clinical trial, regulatory, imaging, and analytics solutions to global sponsors and CROs. Calyx is recognized for reliability and speed in solving clinical development challenges and supporting regulatory compliance.

Therapeutic areas: ImmunologyInfectious DiseasesRare DiseasesCardiovascularOncologyNeurology
Modalities: Small moleculeBiologicAntibodyGene therapymRNA-based drugsMonoclonal antibodyCell therapyVaccine
Industry: Contract Research Organization

Partnerships

Major partnerships with global pharmaceutical, biotech, and clinical research organizations

Beyond the preview

Go deeper on Calyx.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Calyx.

Explore the full profile